| scholarly article | Q13442814 |
| P50 | author | Cornelia Lass-Florl | Q87722456 |
| Manuel Cuenca-Estrella | Q88815674 | ||
| David S Perlin | Q104479284 | ||
| P2093 | author name string | Guillermo Garcia-Effron | |
| Maiken Cavling Arendrup | |||
| Alicia Gomez Lopez | |||
| Juan-Luis Rodriguez-Tudela | |||
| P2860 | cites work | Epidemiology of invasive candidiasis: a persistent public health problem | Q29616758 |
| Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. | Q30452376 | ||
| Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry | Q33445758 | ||
| One year prospective survey of Candida bloodstream infections in Scotland. | Q33910250 | ||
| Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates | Q33938068 | ||
| Detection of resistance to amphotericin B in Candida isolates by using Iso-Sensitest broth | Q33982529 | ||
| Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis | Q34006585 | ||
| Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. | Q34042232 | ||
| Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of candida species | Q34142465 | ||
| Anidulafungin versus fluconazole for invasive candidiasis | Q34580316 | ||
| Acquired resistance to echinocandins in Candida albicans: case report and review | Q34623936 | ||
| Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. | Q34680777 | ||
| Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. | Q34936576 | ||
| Serum differentially alters the antifungal properties of echinocandin drugs | Q35840860 | ||
| Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006 | Q36424929 | ||
| Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment | Q36703038 | ||
| Detection of caspofungin resistance in Candida spp. by Etest. | Q36747567 | ||
| Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. | Q36845482 | ||
| Resistance to echinocandin-class antifungal drugs | Q36849595 | ||
| Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing | Q36870777 | ||
| Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. | Q36933000 | ||
| Increasing incidence of Candida parapsilosis candidemia with caspofungin usage | Q37032961 | ||
| Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. | Q37115801 | ||
| Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program | Q37420953 | ||
| A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility | Q39686624 | ||
| Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. | Q40524039 | ||
| Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints | Q41787736 | ||
| In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. | Q41810114 | ||
| Breakpoints for susceptibility testing should not divide wild-type distributions of important target species | Q41928002 | ||
| Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility | Q41957394 | ||
| Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2) | Q42132063 | ||
| Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint | Q42545839 | ||
| A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus | Q42740228 | ||
| Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection | Q43438479 | ||
| Comparison of caspofungin and amphotericin B for invasive candidiasis | Q44255071 | ||
| A one-year survey of candidemia in Belgium in 2002. | Q45214183 | ||
| Invasive Candida species infections: a 5 year population-based assessment | Q46616044 | ||
| Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility | Q46738286 | ||
| Emergence of Candida tropicalis resistant to caspofungin | Q46891948 | ||
| Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis | Q46933146 | ||
| Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. | Q53596680 | ||
| Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial | Q56970523 | ||
| Time to Initiation of Fluconazole Therapy Impacts Mortality in Patients with Candidemia: A Multi‐Institutional Study | Q61833672 | ||
| In vivo pathogenicity of eight medically relevant Candida species in an animal model | Q78379219 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Candida | Q131260 |
| P304 | page(s) | 426-439 | |
| P577 | publication date | 2009-11-02 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media | |
| P478 | volume | 54 |
| Q34041471 | A novel flucytosine-resistant yeast species, Candida pseudoaaseri, causes disease in a cancer patient |
| Q36290663 | Acquired Multidrug Antifungal Resistance in Candida lusitaniae during Therapy. |
| Q37273918 | Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates |
| Q42682766 | An Update on Candida tropicalis Based on Basic and Clinical Approaches |
| Q38511946 | Antifungal drug resistance among Candida species: mechanisms and clinical impact |
| Q36171475 | Assessment of accuracy of identification of pathogenic yeasts in microbiology laboratories in the United kingdom |
| Q33767746 | Candida palmioleophila: characterization of a previously overlooked pathogen and its unique susceptibility profile in comparison with five related species. |
| Q41833091 | Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints |
| Q39041926 | Caspofungin MIC Distribution amongst Commonly Isolated Candida Species in a Tertiary Care Centre - An Indian Experience |
| Q37036603 | Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure |
| Q38586680 | Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes |
| Q33830384 | Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. |
| Q35806170 | Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata |
| Q37263358 | Comparison between the EUCAST procedure and the Etest for determination of the susceptibility of Candida species isolates to micafungin |
| Q39092102 | Comparison of EUCAST and CLSI Reference Microdilution MICs of Eight Antifungal Compounds for Candida auris and Associated Tentative Epidemiological Cutoff Values. |
| Q40345973 | Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. |
| Q42738231 | Comparison of caspofungin MICs by means of EUCAST method EDef 7.1 using two different concentrations of glucose |
| Q36118827 | Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology |
| Q45852198 | Comparison of the Etest and a rapid flow cytometry-based method with the reference CLSI broth microdilution protocol M27-A3 for the echinocandin susceptibility testing of Candida spp. |
| Q41640129 | Comparison of three statistical methods for establishing tentative wild-type population and epidemiological cutoff values for echinocandins, amphotericin B, flucytosine, and six Candida species as determined by the colorimetric Sensititre YeastOne m |
| Q40045673 | Culture-Independent Molecular Methods for Detection of Antifungal Resistance Mechanisms and Fungal Identification |
| Q37554055 | Current perspectives on echinocandin class drugs |
| Q56934885 | Definitions and Epidemiology of Candida Species not Susceptible to Echinocandins |
| Q50044343 | Development of echinocandin resistance in Candida tropicalis following short-term exposure to caspofungin for empiric therapy. |
| Q40202924 | Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species |
| Q35941237 | Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations |
| Q35065859 | Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin |
| Q57651693 | EUCAST and CLSI: How to Assess in Vitro Susceptibility and Clinical Resistance |
| Q37822777 | Echinocandin antifungal drugs in fungal infections: a comparison |
| Q38027469 | Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches. |
| Q38254290 | Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management |
| Q28544739 | Echinocandin resistance: an emerging clinical problem? |
| Q35140020 | Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden. |
| Q42706331 | Echinocandin susceptibility testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots. |
| Q38633102 | Echinocandins: The Expanding Antifungal Armamentarium |
| Q37892184 | Echinocandins: addressing outstanding questions surrounding treatment of invasive fungal infections |
| Q42710734 | Epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole for six Candida species as determined by the colorimetric Sensititre YeastOne method |
| Q35959495 | Epidemiology and antifungal resistance in invasive candidiasis |
| Q36385474 | Etest and Sensititre YeastOne Susceptibility Testing of Echinocandins against Candida Species from a Single Center in Austria |
| Q37925096 | European expert opinion on the management of invasive candidiasis in adults |
| Q42027420 | Evaluation of CLSI M44-A2 disk diffusion and associated breakpoint testing of caspofungin and micafungin using a well-characterized panel of wild-type and fks hot spot mutant Candida isolates |
| Q55510215 | Evaluation of a novel oxiconazole nitrate formulation: The thermosensitive gel. |
| Q42529877 | Evaluation of caspofungin susceptibility testing by the new Vitek 2 AST-YS06 yeast card using a unique collection of FKS wild-type and hot spot mutant isolates, including the five most common candida species |
| Q50048553 | Fungemia Surveillance in Denmark Demonstrates Emergence of Candida non-albicans, Higher Antifungal Usage and Resistance Rates When Compared to Other Nations |
| Q42035300 | Improved detection of Candida sp. fks hot spot mutants by using the method of the CLSI M27-A3 document with the addition of bovine serum albumin |
| Q92641250 | In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017 |
| Q41989571 | In vitro activity of echinocandins against 562 clinical yeast isolates from a Romanian multicentre study. |
| Q37855152 | In vitro activity of echinocandins against non-Candida albicans: is echinocandin antifungal activity the same? |
| Q41511867 | In vitro activity of two amphotericin B formulations against Malassezia furfur strains recovered from patients with bloodstream infections |
| Q36856930 | Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations |
| Q51027528 | Influence of serum on in vitro susceptibility testing of echinocandins for Candida parapsilosis and Candida guilliermondii. |
| Q42092940 | Multicenter Comparison of the Etest and EUCAST Methods for Antifungal Susceptibility Testing of Candida Isolates to Micafungin. |
| Q37538775 | Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method |
| Q37544819 | Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method. |
| Q28743556 | National surveillance of fungemia in Denmark (2004 to 2009) |
| Q40106799 | Oral candidiasis among African human immunodeficiency virus-infected individuals: 10 years of systematic review and meta-analysis from sub-Saharan Africa |
| Q39033115 | Pan-azole-resistant Candida tropicalis carrying homozygous erg11 mutations at position K143R: a new emerging superbug? |
| Q37785979 | Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections |
| Q41893115 | Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008). |
| Q36172242 | Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012 |
| Q35757564 | Quick Detection of FKS1 Mutations Responsible for Clinical Echinocandin Resistance in Candida albicans |
| Q39464983 | Rapid Detection of FKS-Associated Echinocandin Resistance in Candida glabrata |
| Q64125904 | Rationale for a Neisseria gonorrhoeae Susceptible Only Interpretive Breakpoint for Azithromycin |
| Q33622743 | Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates. |
| Q36018829 | Recurrent episodes of candidemia due to Candida glabrata with a mutation in hot spot 1 of the FKS2 gene developed after prolonged therapy with caspofungin |
| Q26783197 | SUSCEPTIBILITY TEST FOR FUNGI: CLINICAL AND LABORATORIAL CORRELATIONS IN MEDICAL MYCOLOGY |
| Q46243493 | Sequencing of FKS Hot-Spot1 from Saprochaete capitata. Searching for a relationship with reduced echinocandin susceptibility |
| Q42118113 | Set of classical PCRs for detection of mutations in Candida glabrata FKS genes linked with echinocandin resistance |
| Q47685703 | Seven years of clinical experience with the Yeast Traffic Light PNA FISH: Assay performance and possible implications on antifungal therapy |
| Q39665961 | Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study |
| Q58573711 | Susceptibility Screening of Hyphae-Forming Fungi with a New, Easy, and Fast Inoculum Preparation Method |
| Q61799865 | Susceptibility breakpoint for Danofloxacin against swine Escherichia coli |
| Q57036254 | The association between treatment appropriateness according to EUCAST and CLSI breakpoints and mortality among patients with candidemia: a retrospective observational study |
| Q89638834 | The effect of aqueous and ethanolic extract of Iranian propolis on Candida Albicans isolated from the mouth of patients with colorectal malignancy undergone chemotherapy: An in-vitro study |
| Q38258833 | The future of fungal susceptibility testing |
| Q36172500 | The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata |
| Q37170218 | Treatment of invasive candidiasis in the elderly: a review |
| Q47355716 | Update from a twelve-year nationwide fungaemia surveillance: increasing intrinsic and acquired resistance causes concern. |
| Q43125888 | Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria |
| Q42146367 | Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin |
| Q41908678 | Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria |
Search more.